Virax Biolabs Group Limited (VRAX) AI Stock Analysis

Virax Biolabs Group Limited is a London-based biotechnology company that sells, distributes, and markets diagnostic test kits, medical technology, and personal protective equipment. The company focuses on the prevention, detection, diagnosis, and risk management of viral diseases in immunology. Under its ViraxClear brand, it offers rapid antibody, antigen, PCR, and neutralizing antibody tests for clinics, pharmacies, laboratories, and hospitals across Europe, South America, Asia Pacific, and Sub-Saharan Africa. Through its ViraxCare brand, it supplies employee protection products including infrared thermometers, pulse oximeters, masks, gloves, nebulizing machines, and smart wearable devices via an online platform.

Revenue has fluctuated significantly, showing a 5-year CAGR of -34.1% from FY2020 to FY2026. In FY2024, revenue reached $156,419 before dropping 96.0% in FY2025 to $6,331. For FY2026, revenue increased 96.2% to $12,423, accompanied by a gross margin of 61.9% and an operating margin of -51515.2%. Net income remained negative at -$5.0M in FY2026, following losses of -$6.1M in FY2025 and -$6.7M in FY2024. For the latest quarter ending June 30, 2026, quarterly revenue growth was 684.9% year-over-year, while trailing twelve months earnings per share stood at -$12.64.

As of June 30, 2026, Virax Biolabs held $6.5M in cash and short-term investments against total debt of $414,387, resulting in net cash of $6.1M. Shareholders' equity was $7.6M out of $8.3M in total assets, supported by a current ratio of 9.97 and a debt-to-equity ratio of 0.05. In FY2026, the company reported operating cash flow of -$4.6M and free cash flow of -$4.9M, while spending $255,830 on capital expenditures.

Virax Biolabs trades at a price-to-sales multiple of 157.0x, significantly higher than the 4.1x median of its US-listed Healthcare peers. Its enterprise value stands at -$4.0M with an EV/EBITDA multiple of 0.4x, compared to the peer median of 12.0x, and a price-to-book ratio of 0.3x. The company's market capitalization is $2.0M at a closing price of $1.45. Over the past year, the stock declined 90.6%, lagging the S&P 500 (SPY), which gained 16.8% over the same period.

Wall Street coverage includes a mean price target of $25.00, representing a 1624.1% increase over the last close of $1.45. For the current fiscal year ending March 31, 2027, consensus estimates forecast revenue of $4,000 and an EPS estimate of -$6.00, reflecting expected EPS growth of 52.5%. Over the last 4 quarters, the company recorded 0 EPS beats against consensus estimates.

This page is an AI-written research summary of Virax Biolabs Group Limited (VRAX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: VRAX income statement, VRAX balance sheet, VRAX key metrics, VRAX analyst forecast, VRAX chart. See the VRAX stock overview for the latest quote and news.